|drug985||Pathogen-specific aAPC Wiki||1.00|
|D014777||Virus Diseases NIH||0.13|
|D018352||Coronavirus Infections NIH||0.05|
There is one clinical trial.
The purpose of this study is to evaluate the efficacy and safety of favipiravir combined with tocilizumab in the treatment of corona virus disease 2019.
Description: Definition of clinical cure: The viral load of the respiratory specimen was negative for two consecutive times (the interval between the two tests was greater than or equal to one day), the lung image improved, and the body temperature returned to normal for more than 3 days, and the clinical manifestation improved.Measure: Clinical cure rate Time: 3 months